Intellia Therapeutics and Regeneron Pharmaceuticals have announced a collaboration to co-develop new therapies, which will require review and approval from the FDA.
1 report, 1 independent
Updated Jun 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Intellia Therapeutics and Regeneron Pharmaceuticals have announced a collaboration to co-develop new therapies, which will require review and approval from the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Regeneron conducted the clinical trial for a study related to co-developing new therapies.Sub-event
Intellia and Regeneron are partnering to co-develop therapies, with FDA approval being the next step.1 source
Keep exploring
The entities involved
-
Intellia Therapeutics
It is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system.
-
Regeneron Pharmaceuticals
American pharmaceutical company
- FDA